Dr. Joshua Hare to Chair the Board
LA JOLLA, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today the formation of a Medical Advisory Board to provide clinical guidance for the Company's development program of CDP-1050 for the treatment of heart failure.
The Medical Advisory Board will play an important supportive role in the design and oversight of the planned CDP-1050 Phase 2 clinical trial and assist in addressing regulatory and patients' welfare issues. It is composed of internationally recognized leaders in the field of heart failure; all of whom have extensive experience in the design and execution of clinical trials aimed at improved care of patients with heart failure.
CDP-1050 is being developed as a new therapeutic modality in the management of heart failure. It targets the redox-nitiric oxide imbalance, which is increasingly recognized as a major factor in poor myocardial contractile efficiency, the hallmark manifestation of this disorder.
The Medical Advisory Board is chaired by Joshua M. Hare, M.D., the Louis Lemberg Professor of Medicine, Chief of the Division of Cardiology, and Director of the Interdisciplinary Stem Cell Institute at University of Miami, Miller School of Medicine. He has pioneered the use of stem cell therapy to repair damaged hearts. Dr. Hare has authored and co-authored numerous peer-reviewed publications including a report on a multi-center clinical trial with oxypurinol, a modifier of cellular redox potential, in patients with symptomatic heart failure. He served as the principal investigator of that clinical trial. Dr. Hare has also authored a New England Journal of Medicine editorial on redox-nitric oxide balance in the cardiovascular system.
Other members of the Medical Advisory Board include:
Wilson S. Colucci, M.D., is the Thomas J. Ryan Professor ofPage: 1 2 3 4 5 Related biology technology :1
. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 292
. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.3
. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory4
. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes5
. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results6
. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court7
. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results8
. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML9
. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 200710
. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 200711
. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results